专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080226554A1 Methods For Detecting Markers Associated With Endometrial Disease or Phase 审中-公开
标题翻译：检测与子宫内膜异位症相关的标记物的方法
公开(公告)号：US20080226554A1
公开(公告)日：2008-09-18
申请号：US10584207
申请日：2004-12-21
申请人： Terence J. Colgan , Michael K.W. Siu , Alexander D. Romaschin , Eric C.C. Yang
发明人： Terence J. Colgan , Michael K.W. Siu , Alexander D. Romaschin , Eric C.C. Yang
IPC分类号： A61K49/00 , C12Q1/00 , C12Q1/68 , C07K2/00 , G01N33/567
CPC分类号： G01N33/57442 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57484 , G01N33/6893 , G01N2800/364 , G01N2800/367 , G01N2800/368
摘要： Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for endometrial diseases employing endometrial markers, polynucleotides encoding the markers, and/or binding agents for the markers.
摘要翻译：描述了检测受试者子宫内膜疾病或子宫内膜期的方法，其包括测量子宫内膜标志物或编码来自受试者的样品中的标记物的多核苷酸。本发明还提供子宫内膜疾病的定位或成像方法以及用于实施本发明的方法的试剂盒。本发明还考虑了使用子宫内膜标志物，编码标记物的多核苷酸和/或用于标记物的结合剂的子宫内膜疾病的治疗应用。

2. 发明授权

US06203997B1 Quantitation of analytes in whole blood 有权
标题翻译：全血分析物的定量分析
公开(公告)号：US06203997B1
公开(公告)日：2001-03-20
申请号：US09457465
申请日：1999-12-08
申请人： Alexander D. Romaschin , Paul M. Walker
发明人： Alexander D. Romaschin , Paul M. Walker
IPC分类号： G01N3353
CPC分类号： G01N33/5091 , G01N33/56911 , G01N33/582 , Y10S435/962 , Y10S435/968 , Y10S435/975
摘要： The invention relates to a method for quantitating the level of a preselected analyte in a sample of blood of a human or animal patient by incubating the test sample with an antibody specific to the analyte to form an immunocomplex, which then interacts with the white blood cell fractions and result in the production of oxidants. Oxidants are detected using chemiluminescent reagents. In addition, the white blood cell oxidant response may be enhanced by the inclusion of certain agents such as opsonized zymosan. As part of the assay, separate blood samples are also maximally stimulated with a maximal stimulatory amount of exogenously-added antigen, and corresponding antibody, to form immunocomplexes, to provide a response factor used in the quantitation of analyte. This quantitative method may be used to determine levels of analytes in a sample of a patient's blood including endotoxin and other analytes related to sepsis, in order to select the proper therapeutic course, or may be used to measure other analytes such as inflammatory mediators, hormones, acute phase proteins, toxins, drugs of abuse, markers of cardiac muscle damage, therapeutic drugs, cytokines, and chemokines.
摘要翻译：本发明涉及通过将测试样品与特异于分析物的抗体孵育以形成免疫复合物（其然后与白细胞相互作用）来定量人或动物患者血液样品中预选分析物的水平的方法导致氧化剂的生成。使用化学发光试剂检测氧化剂。此外，白细胞氧化剂反应可以通过包括某些试剂例如调理的酵母聚糖来增强。作为测定的一部分，分离的血液样品也用最大刺激量的外源加入的抗原和相应的抗体最大程度地刺激以形成免疫复合物，以提供用于定量分析物的响应因子。该定量方法可用于确定患者血液样品中包含内毒素和与败血症有关的其他分析物的样品中的分析物水平，以选择适当的治疗过程，或可用于测量其他分析物，如炎症介质，激素，急性期蛋白，毒素，滥用药物，心肌损伤标志物，治疗药物，细胞因子和趋化因子。

3. 发明授权

US06306614B1 Measurement of analytes in whole blood 有权
标题翻译：测量全血中的分析物
公开(公告)号：US06306614B1
公开(公告)日：2001-10-23
申请号：US09353189
申请日：1999-07-14
申请人： Alexander D. Romaschin , Paul M. Walker
发明人： Alexander D. Romaschin , Paul M. Walker
IPC分类号： G01N3353
CPC分类号： G01N33/53 , G01N33/5091 , G01N33/569 , G01N33/56911 , G01N33/5768 , G01N33/582 , G01N33/6869 , Y02A50/54 , Y10S435/962 , Y10S435/968 , Y10S435/975 , Y10S436/808 , Y10S436/811
摘要： The invention relates to a method for measuring the level of a preselected analyte in a sample of blood of a human or animal patient by incubating the test sample with an antibody specific to the analyte to form an immunocomplex, which then interacts with the white blood cell fractions and result in the production of oxidants. Oxidants are detected using chemiluminescent reagents. The assay is performed on the sample and in addition includes a measurement of the oxidant production resulting from a maximal stimulatory dose of immunocomplexes, providing a ratio to indicate the level of analyte in the sample. The white blood cell oxidant response may be enhanced by the inclusion of certain agents such as zymosan. This method may be used to determine levels of analytes in a sample of a patient's blood including endotoxin and other analytes related to sepsis, in order to select the proper therapeutic course, or may be used to measure other analytes such as inflammatory mediators, hormones, acute phase proteins, toxins, drugs of abuse, markers of cardiac muscle damage, therapeutic drugs, cytokines, and chemokines. Additional parameters derived from the assay include maximal chemiluminscent response and responsiveness to aid in the staging of sepsis.
摘要翻译：本发明涉及通过将测试样品与分析物特异的抗体孵育以形成免疫复合物（其然后与白细胞相互作用）来测量人或动物患者血液样品中预选分析物的水平的方法导致氧化剂的生成。使用化学发光试剂检测氧化剂。对样品进行测定，另外包括由最大刺激剂量的免疫复合物产生的氧化剂生成的测量值，提供指示样品中分析物水平的比率。白细胞氧化剂反应可以通过包含某些试剂例如酵母聚糖来增强。该方法可以用于确定患者血液样品中的分析物的水平，包括与脓毒症相关的内毒素和其他分析物，以选择适当的治疗过程，或可用于测量其它分析物，例如炎症介质，激素，急性期蛋白，毒素，滥用药物，心肌损伤标志物，治疗药物，细胞因子和趋化因子。从该测定得到的附加参数包括最大化学发光反应和响应性以帮助脓毒症分期。

4. 发明授权

US6159683A Method of determining stage of sepsis 失效
标题翻译：确定败血症阶段的方法
公开(公告)号：US6159683A
公开(公告)日：2000-12-12
申请号：US991109
申请日：1997-12-16
申请人： Alexander D. Romaschin , Paul M. Walker
发明人： Alexander D. Romaschin , Paul M. Walker
IPC分类号： G01N33/569 , C12Q1/70 , C12Q1/10 , G01N33/53 , G01N33/563
CPC分类号： G01N33/56911 , G01N2333/525 , G01N2400/50 , Y10S435/962 , Y10S435/968 , Y10S435/973 , Y10S435/975 , Y10S436/808 , Y10S436/811
摘要： The invention relates to a method for staging sepsis in a patient by concurrently measuring in a sample of the patient's blood four parameters which are indicative of the stage of sepsis: 1) the level of microbial product level in the blood; 2) the level of tumor necrosis factor (TNF) response reserve; 3) the maximum oxidant production by neutrophils, and 4) the responsiveness of the patient's neutrophils to immunocomplexes. Based on determining the stage of sepsis, appropriate treatment for the patient may be identified.
摘要翻译：本发明涉及通过在患者血液样本中同时测量脓毒症阶段的四个参数来分级患者的败血症的方法：1）血液中微生物产物水平的水平; 2）肿瘤坏死因子（TNF）反应储备水平; 3）中性粒细胞产生的氧化剂最大，4）患者嗜中性粒细胞对免疫复合物的反应。根据确定败血症的阶段，可以确定患者的适当治疗。

5. 发明申请

US20120251451A1 Renal Cell Carcinoma Biomarkers 审中-公开
标题翻译：肾细胞癌生物标志物
公开(公告)号：US20120251451A1
公开(公告)日：2012-10-04
申请号：US13330421
申请日：2011-12-19
申请人： K.W. Michael SIU , Leroi V. Desouza , George M. Yousef , Alexander D. Romaschin
发明人： K.W. Michael SIU , Leroi V. Desouza , George M. Yousef , Alexander D. Romaschin
IPC分类号： G01N21/64 , A61K49/00 , C40B40/06 , C40B30/04 , G01N21/76
CPC分类号： G01N33/57438 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N2500/00 , G01N2800/52 , G01N2800/56
摘要： The invention provides markers for renal cancer, polynucleotides encoding same, and precursors thereof. The invention also provides methods for detecting, diagnosing, screening for, monitoring, assessing, and treating renal cancers and related disease conditions in a subject. The invention further provides a method of selecting for or assessing efficacy of agents against renal cancer, and a method for assessing renal cancer cell carcinogenic potential of a compound. The invention further provides localization and imaging methods for renal cancers. Also provided are diagnostic compositions and kits for carrying out methods of the invention. In addition, the invention provides therapeutic applications for renal cancers which employ protein renal cancer markers and polynucleotides encoding same, miRNA renal cancer markers and precursors thereof, and binding agents for the markers.
摘要翻译：本发明提供肾癌标记物，编码其的多核苷酸及其前体。本发明还提供用于检测，诊断，筛选，监测，评估和治疗受试者中的肾癌和相关疾病状况的方法。本发明进一步提供了选择或评估药物对肾癌的功效的方法，以及评估化合物的肾癌细胞致癌潜力的方法。本发明还提供了肾癌的定位和成像方法。还提供了用于实施本发明方法的诊断组合物和试剂盒。此外，本发明提供了使用蛋白质肾癌标记物和编码其的多核苷酸，miRNA肾癌标记物及其前体以及用于标记物的结合剂的肾癌的治疗应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式